Halozyme Therapeutics’ (HALO) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Halozyme Therapeutics (NASDAQ:HALO) in a research report sent to investors on Wednesday morning,Benzinga reports. HC Wainwright currently has a $115.00 price objective on the biopharmaceutical company’s stock.

HALO has been the topic of several other reports. Leerink Partners upgraded shares of Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and increased their price target for the stock from $83.00 to $110.00 in a research report on Friday, August 7th. Morgan Stanley cut their price objective on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a research report on Tuesday, May 12th. Benchmark restated a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, July 21st. Citizens Jmp raised their target price on Halozyme Therapeutics from $92.00 to $93.00 and gave the stock a “market outperform” rating in a report on Friday, August 7th. Finally, Weiss Ratings upgraded Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research report on Monday. Nine equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Halozyme Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $91.20.

Halozyme Therapeutics Price Performance

NASDAQ HALO opened at $110.19 on Wednesday. Halozyme Therapeutics has a 52 week low of $61.22 and a 52 week high of $111.15. The firm has a market capitalization of $12.51 billion, a P/E ratio of 32.89, a PEG ratio of 0.43 and a beta of 0.88. The company has a quick ratio of 2.31, a current ratio of 2.71 and a debt-to-equity ratio of 13.50. The company has a 50-day moving average price of $90.76 and a 200-day moving average price of $75.82.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, topping the consensus estimate of $1.79 by $0.49. The firm had revenue of $481.00 million for the quarter, compared to analysts’ expectations of $402.28 million. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The business’s quarterly revenue was up 47.7% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.54 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Equities research analysts anticipate that Halozyme Therapeutics will post 7.98 earnings per share for the current year.

Insider Buying and Selling at Halozyme Therapeutics

In other news, CEO Helen Torley sold 20,000 shares of the stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $104.18, for a total value of $2,083,600.00. Following the completion of the sale, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at $79,987,320.40. This represents a 2.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mahesh Krishnan sold 7,304 shares of the firm’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $75.00, for a total transaction of $547,800.00. Following the sale, the director owned 14,462 shares in the company, valued at $1,084,650. The trade was a 33.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 32,478 shares of company stock valued at $3,076,604 over the last 90 days. 2.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of HALO. Measured Wealth Private Client Group LLC raised its holdings in Halozyme Therapeutics by 51.5% during the fourth quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 124 shares during the period. Larson Financial Group LLC boosted its stake in shares of Halozyme Therapeutics by 3,118.2% in the third quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 343 shares during the period. MidFirst Bank bought a new position in shares of Halozyme Therapeutics in the second quarter worth about $27,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in shares of Halozyme Therapeutics during the second quarter worth about $28,000. Finally, Quantbot Technologies LP purchased a new stake in shares of Halozyme Therapeutics during the second quarter worth about $30,000. Institutional investors own 97.79% of the company’s stock.

Key Stories Impacting Halozyme Therapeutics

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Analyst maintains Buy rating: HC Wainwright reaffirmed its Buy rating on Halozyme Therapeutics, supporting the bullish view of the company’s growth outlook. HC Wainwright Reaffirms Buy Rating for Halozyme Therapeutics
• Positive Sentiment: Higher earnings expectations: Zacks Research raised its FY2026 EPS forecast to $8.24 from $7.56, above the provided consensus estimate of $7.98. It also lifted forecasts for several 2027 and 2028 quarters, including FY2027 EPS to $9.01 from $8.96, indicating improving expectations for Halozyme’s earnings trajectory. Zacks Research Issues Positive Forecast for HALO Earnings
• Positive Sentiment: Value and growth appeal: Zacks included HALO among four high-growth stocks with discounted PEG ratios for 2026. The designation may attract investors seeking earnings growth at a relatively reasonable valuation, particularly after Halozyme’s strong recent results and revenue growth. 4 High-Growth GARP Stocks With Discounted PEG Ratios for 2026
• Neutral Sentiment: Momentum has been strong: HALO recently hit a new one-year high, reflecting investor enthusiasm and continued upward momentum. However, trading near that high can also increase sensitivity to profit-taking and valuation concerns. Halozyme Therapeutics Hits New 1-Year High
• Negative Sentiment: One longer-term estimate was trimmed: Zacks lowered its FY2028 EPS forecast to $10.06 from $10.21, a minor reduction that partially offsets the otherwise positive revisions.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.